Earlier Thursday, Virios Therapeutics Said After FDA Guidance On The Plan To Progress IMC-1 To Phase 3 Study For Fibromyalgia, Several Life Science Companies Are Engaged, Reviewing Phase 2 Data And Proposed Phase 3 Program For A Potential Partnership
Portfolio Pulse from Benzinga Newsdesk
Virios Therapeutics has received FDA guidance to progress IMC-1 to Phase 3 study for Fibromyalgia. Several life science companies are reviewing Phase 2 data and proposed Phase 3 program for a potential partnership. Virios has also submitted briefing materials to the FDA for a proposed investigational new drug application for IMC-2 as a treatment for Long-COVID. The company has filed for intellectual property protection for IMC-2 as treatment for LC and Alzheimer’s disease, which if granted, provides coverage to at least 2043. The company expects to have capital to support operations into Q3 of 2024.
November 02, 2023 | 2:58 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Virios Therapeutics is progressing with its drug development programs, which could potentially lead to partnerships and new treatments for Fibromyalgia, Long-COVID, and Alzheimer’s disease. This could have a positive impact on the company's stock.
The news about Virios Therapeutics progressing with its drug development programs and potential partnerships is directly related to the company's core business. This could lead to increased revenues in the future, which would likely have a positive impact on the company's stock price.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100